Drug intelligence / Profile preview

ADC2616

Development stage: Preclinical
Lead developer: Hangzhou Adcoris Biopharmaceuticals
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ADC2616 is an investigational bispecific, dual-payload antibody-drug conjugate (BsADC) being developed by Hangzhou Adcoris Biopharmaceuticals. It is designed for a dual-neuroendocrine tumor strategy, specifically targeting small cell lung cancer (SCLC) and other neuroendocrine tumors. The specific targets and payloads of ADC2616 have not been publicly disclosed.

Beyond the preview

Go deeper on ADC2616.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADC2616.

Explore the full profile